TipRanks
Advertisement
Advertisement

DE:VX1 Stock Latest News

Vertex Pharmaceuticals price target raised to $615 from $585 at UBS
The FlyVertex Pharmaceuticals price target raised to $615 from $585 at UBS
2d ago
VRTX
Vertex Pharmaceuticals price target raised to $615 from $585 at UBS
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $615 from $585 at UBS
3d ago
VRTX
Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed
PremiumRatings
Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed
8d ago
VRTX
Vertex Top Pick Affirmed as Inaxaplin Progress Supports Pipeline Upside; $672 Price Target Reiterated
PremiumRatings
Vertex Top Pick Affirmed as Inaxaplin Progress Supports Pipeline Upside; $672 Price Target Reiterated
8d ago
VRTX
Truist sees ‘significant positive readthrough’ for Maze from Vertex data
PremiumThe Fly
Truist sees ‘significant positive readthrough’ for Maze from Vertex data
9d ago
MAZE
VRTX
Maze jumps 25% to $27.99 after Vertex kidney disease data
PremiumThe FlyMaze jumps 25% to $27.99 after Vertex kidney disease data
9d ago
MAZE
VRTX
Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study
Premium
The Fly
Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study
9d ago
VRTX
Vertex Pharmaceuticals partners with Lindsey Vonn for JOURNAVX awareness
Premium
The Fly
Vertex Pharmaceuticals partners with Lindsey Vonn for JOURNAVX awareness
16d ago
VRTX
Vertex Pharmaceuticals reinstated with an Overweight at JPMorgan
PremiumThe Fly
Vertex Pharmaceuticals reinstated with an Overweight at JPMorgan
20d ago
VRTX
Arcturus Therapeutics price target raised to $41 from $20 at Roth Capital
PremiumThe Fly
Arcturus Therapeutics price target raised to $41 from $20 at Roth Capital
29d ago
ARCT
VRTX
Vertex Pharmaceuticals resumed with an Overweight at Morgan Stanley
PremiumThe Fly
Vertex Pharmaceuticals resumed with an Overweight at Morgan Stanley
30d ago
VRTX
Vertex Pharmaceuticals completes acquisition of Crinetics Pharmaceuticals
PremiumThe Fly
Vertex Pharmaceuticals completes acquisition of Crinetics Pharmaceuticals
1M ago
CRNX
VRTX
Vertex Pharmaceuticals added to US Conviction List at Goldman Sachs
PremiumThe FlyVertex Pharmaceuticals added to US Conviction List at Goldman Sachs
1M ago
VRTX
Argenx price target raised to $1,250 from $1,230 at Morgan Stanley
Premium
The Fly
Argenx price target raised to $1,250 from $1,230 at Morgan Stanley
1M ago
ARGX
VRTX
Private Markets: $1B for Base Power, $545M for Whatnot
Premium
The Fly
Private Markets: $1B for Base Power, $545M for Whatnot
1M ago
U
GD
Private Markets: Databricks secures $5B as Kalshi targets $40B valuation
PremiumThe Fly
Private Markets: Databricks secures $5B as Kalshi targets $40B valuation
2M ago
AI
IBM
Vertex: Competitive Threat Eases, Pipeline Strength Supports Unchanged $600 Price Target and Buy Rating
PremiumRatings
Vertex: Competitive Threat Eases, Pipeline Strength Supports Unchanged $600 Price Target and Buy Rating
2M ago
VRTX
Vertex Pharmaceuticals added to ‘US 1 List’ at BofA
PremiumThe Fly
Vertex Pharmaceuticals added to ‘US 1 List’ at BofA
2M ago
VRTX
Sionna Therapeutics downgraded to Neutral at Guggenheim after trial miss
PremiumThe Fly
Sionna Therapeutics downgraded to Neutral at Guggenheim after trial miss
2M ago
SION
VRTX
Vertex Pharmaceuticals price target raised to $672 from $605 at BofA
PremiumThe FlyVertex Pharmaceuticals price target raised to $672 from $605 at BofA
2M ago
SION
VRTX
Early notable gainers among liquid option names on August 10th
Premium
The Fly
Early notable gainers among liquid option names on August 10th
2M ago
APA
AKAM
Vertex Pharmaceuticals price target raised to $565 from $560 at Truist
Premium
The Fly
Vertex Pharmaceuticals price target raised to $565 from $560 at Truist
2M ago
VRTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >